

In the Claims:

Please cancel claims 9 and 11-14, without prejudice.

Claim 1 (Previously presented). A modified botulinum toxin comprising at least one phosphorylation site added to the toxin as a secondary modification site, wherein the modified botulinum toxin is structurally different from a naturally occurring botulinum toxin.

Claim 2 (Previously presented). A modified botulinum toxin comprising one or more secondary modification sites in addition to the ones that are already naturally present.

Claim 3 (Previously presented). The modified botulinum toxin of claim 2, wherein the secondary modification site is a member selected from the group consisting of N-glycosylation, casein kinase II (CK-2) phosphorylation, N-terminal myristylation, protein kinase C (PKC) phosphorylation and tyrosine phosphorylation sites.

Claim 4 (Previously presented). A modified botulinum toxin devoid of one or more secondary modification sites that are found in an identical naturally existing neurotoxin.

Claim 5 (Original). The modified neurotoxin of claim 4, wherein the secondary modification site is a member selected from the group consisting of N-glycosylation, casein kinase II (CK-2) phosphorylation, N-terminal myristylation, protein kinase C (PKC) phosphorylation and tyrosine phosphorylation sites.

Claim 6 (Previously presented). The modified neurotoxin of claim 2, wherein the structural modification is effective to increase the biological persistence of the modified neurotoxin relative to an identical neurotoxin without the structural modification.

**DOCKET NO.: ALLE0005-100
(17376 BOT)**

PATENT

Claim 7 (Previously presented). The modified neurotoxin of claim 2, wherein the structural modification is effective to decrease the biological persistence of the modified neurotoxin relative to an identical neurotoxin without the structural modification.

Claims 8-9 (Cancelled).

Claim 10 (Previously presented). A modified botulinum toxin comprising at least one N-glycosylation site as a secondary modification site in addition to any N-glycosylation site that is naturally occurring on an unmodified neurotoxin wherein the modified botulinum toxin is structurally different from a naturally occurring neurotoxin.

Claims 11-14 (Cancelled).